Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Passage Bio, Inc.

Initiate the clinical trial for PBKR03

Not delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
11 Jan 2021
Due
30 Jun 2021
Checked
24 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Clinical trial initiation in 1H21”

What we found

Evidence strength A What the grades mean

The company failed to initiate the PBKR03 clinical trial by the first half of 2021, subsequently pushing the expected initiation date to the third and then fourth quarter of 2021.

  • A
    Passage Bio, Inc. 10-Q filed 2021-08-05 Regulatory filing · published 5 Aug 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 6f7f9e376000
    “We expect to initiate our GALax-C Trial in the third quarter of 2021” ✓ confirmed on the page
  • A
    Passage Bio, Inc. 10-Q filed 2021-11-04 Regulatory filing · published 4 Nov 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 336398e5a89e
    “We expect to initiate our GALax-C Trial in the fourth quarter of 2021” ✓ confirmed on the page

Market reaction: the shares moved +2.7% against the S&P 500 over the three sessions around the disclosure (4 Aug 2021 to 9 Aug 2021). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
PBKR03 clinical trial
In the company’s control
Medium
Specificity
High
Depends on
Regulatory, Customer

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
  4. Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Passage Bio, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-PASG-021455 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.